The FDA enforcement database lists Class II recalls, dated 14 October, of compounded tirzepatide and semaglutide injections from two US compounding pharmacies. Several products from one firm combined the GLP-1 drug with cyanocobalamin and were supplied as prefilled single-dose syringes; another firm's product was a multi-dose tirzepatide vial. The stated reason is lack of assurance of sterility, linked to the use of bacteriostatic water and to processing equipment. The recalls are listed as ongoing.
A Class II recall means the FDA judges that use may cause temporary or medically reversible harm, or that serious harm is unlikely. It is not a finding about tirzepatide or semaglutide themselves, and it does not involve licensed branded pens.
These products were made and distributed in the US. Their direct relevance in India is limited, but compounded and imported GLP-1 products are reaching patients here through informal channels, and the same sterility concern applies to any non-licensed injectable.
- Ask patients on GLP-1 injections where their supply comes from, and whether it is a licensed pen.
- Treat any injection-site infection or unexplained fever in someone using compounded injections as possibly product-related.
- Combined GLP-1 and vitamin B12 syringes are compounded products, not licensed medicines.
- Advise patients to use only licensed products obtained through a pharmacy on prescription.
- The recall concerns sterility of specific batches, not the safety of the drugs themselves.
Why it matters
Demand for GLP-1 drugs has created a grey supply chain where sterility, not pharmacology, is the main risk.
Don't overread it
A Class II recall of compounded batches says nothing about the safety of licensed tirzepatide or semaglutide.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free